We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The research, published in the ACS Infectious Diseases journal on Thursday, showed that vaccine formulations by IISc-incubated biotech start-up Mynvax triggered a strong immune response in mice.